After GetSwift, judge could not hear split trial in Revlimid patent case, court told

Christian Dimitriadis 2021-07-20 8:39 pm By Christine Caulfield | Melbourne

Please login to bookmark

A proposal by Bristol-Myers Squibb-owned Celgene to split a second trial into two more hearings in a dispute over patents covering the pharmaceutical maker’s top selling cancer drug Revlimid would result in wasted costs, wasted time and require a second judge, a court has been told.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au